BFM
NAVB

Boothbay Fund Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Boothbay Fund Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-40,000
Closed -$3.59K – 2142
2023
Q3 		$3.59K Hold
40,000
– – ﹤0.01% 1678
2023
Q2 		$3.68K Buy
+40,000
New +$6.38K ﹤0.01% 1730

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Boothbay Fund Management's NAVB Position: Q4 2023 in Review

Boothbay Fund Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 40,000 shares — an estimated $3.59K sold.

Boothbay Fund Management first reported a position in NAVB in Q2 2023 and held it in 2 quarters. The position peaked at $3.68K in Q2 2023. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Boothbay Fund Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 40,000 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $3.59K.
  • Boothbay Fund Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2023 and held it in 2 quarters.
  • Boothbay Fund Management's Navidea Biopharmaceuticals Inc. position peaked at $3.68K in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.